These data indicated that AOM/DSS-treated Tipe2-deficient mice showed less severe CRC might due to the suppression of iTreg differentiation induced by Tipe2 in naïve CD4+ T cells. The gene discussed is TIPE2; the disease is colorectal carcinoma.